Pharma Execs Urge 'Balance' In China Payer Price Negotiations
Executive Summary
The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.
You may also be interested in...
Shanghai Eyes Commercial Insurance Push To Address Drug Firms’ Pricing Concerns
As Shanghai seeks to develop into an international biopharma hub, the local government is encouraging commercial medical insurers to cover more innovative drugs in their products. The policy aims to provide an alternative solution to dominant pricing by the national public payer, which often imposes deep discounts on novel drugs in exchange for reimbursement coverage.
Cold Water On Already Frozen Sector: Industry Growing Wary Of China Price Cuts
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.
China’s Payer Keeps Deep Price Cuts Steady in Latest NRDL Listing
The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.